Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.

Authors: Panizo, S  Barrio-Vazquez, S  Naves-Diaz, M  Carrillo-Lopez, N  Rodriguez, I  Fernandez-Vazquez, A  Valdivielso, JM  Thadhani, R  Cannata-Andia, JB 
Citation: Panizo S, etal., Nephrol Dial Transplant. 2013 Sep 7.
Pubmed: (View Article at PubMed) PMID:24013683
DOI: Full-text: DOI:10.1093/ndt/gft268

BACKGROUND: Left ventricular hypertrophy (LVH), a common complication in chronic kidney disease (CKD), is associated with high cardiovascular mortality. The aim of this experimental study was to analyze the effect of different vitamin D receptor activators (VDRAs) on both LVH and myocardial fibrosis in chronic renal failure (CRF). METHODS: Male Wistar rats with CRF, carried out by 7/8 nephrectomy, were treated intraperitoneally with equivalent doses of VDRAs (calcitriol, paricalcitol and alfacalcidol, 5 days per week) during 4 weeks. A placebo group (CRF + vehicle) and a Sham group with normal renal function served as controls. Biochemical, morphological, functional and molecular parameters associated with LVH were evaluated, as well as cardiac fibrosis, collagen I, transforming growth factor beta1 (TGFbeta1) and matrix metalloproteinase-1 (MMP1) expression. RESULTS: All VDRAs treatment prevented LVH, with values of cardiomyocyte size, LV wall and septum thickness and heart-body weight ratio similar to those observed in the Sham group. At molecular levels, all VDRAs attenuated atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) expression compared with CRF + vehicle. The phosphorylation of ERK1/2, a signal for activating growth, was stimulated in the CRF + vehicle group; VDRAs use prevented this activation. Paricalcitol was the only VDRA used that maintained in the normal range all parameters associated with myocardial fibrosis (total collagen, collagen I, TGFbeta1 and MMP1). CONCLUSIONS: Our findings demonstrated that the three VDRAs used induced similar changes in bone metabolic parameters and LVH. In addition, paricalcitol was the only VDRA which showed a relevant beneficial effect in the reduction of myocardial fibrosis, a key factor in the myocardial dysfunction in CKD patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 7297044
Created: 2013-09-10
Species: All species
Last Modified: 2013-09-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.